

NOV 06 2006

USSN: 10/730,334
Office Action dated October 4, 2006
Response to OA dated November 6, 2006

VIA FACSIMILE - 571-273-8300
6 pages

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Richard A. Nash et al.

Serial No.: 10/730,334

Group Art Unit No.: 1644

Filed: December 8, 2003

Examiner: P. Gambel

METHODS OF USING FLT3-LIGAND IN HEMATOPOIETIC CELL
For: TRANSPLANTATION PROCEDURES INCORPORATING
NONMYELOABLATIVE CONDITIONING REGIMENS

Docket No.: 3191-A

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

1. Introductory Comments

In response to the Office Action mailed 4 October 2006 and having a due date of 4 November 2006, Applicants submit the following response.

In accordance with the Examiner's species designations, Applicants elect the species of autologous cells, the species of bone marrow as a source of hematopoietic cells, and the species of radiotherapy as the form of a nonmyeloablative conditioning regimen.

Claims 1-25 are currently pending. Claims 12 and 17-25 are drawn to non-elected species and are withdrawn from consideration. Applicants reserve the right to rejoinder in the present application and/or the right to prosecute withdrawn claims in other related applications.

Amendment to the Claims begin on page 2 of this paper.

Remarks begin on page 6 of this paper.